The Action of SDZ 205557 at 5-Hydroxytryptamine

Total Page:16

File Type:pdf, Size:1020Kb

The Action of SDZ 205557 at 5-Hydroxytryptamine Br. J. Pharmacol. (1993), 108, 376-382 19" Macmiflan Press Ltd, 1993 The action of SDZ 205,557 at 5-hydroxytryptamine (5-HT3 and 5-HT4) receptors 1R.M. Eglen, R. Alvarez, L.G. Johnson, E. Leung & E.H.F. Wong Institute of Pharmacology, Syntex Discovery Research, 3401 Hillview Ave, Palo Alto, CA 94304, U.S.A. 1 The interaction of the novel antagonist, SDZ 205,557 (2-methoxy-4-amino-5-chloro benzoic acid 2-(diethylamino) ethyl ester), at 5-HT3 and 5-HT4 receptors has been assessed in vitro and in vivo. 2 In guinea-pig hippocampus and in the presence of 0.4 JLM 5-carboxamidotryptamine, 5-HT4-mediated stimulation of adenylyl cyclase was competitively antagonized by SDZ 205,557, with a pA2 value of 7.5, and a Schild slope of 0.81. In rat carbachol-contracted oesophagus, 5-HT4-receptor mediated relaxations were surmountably antagonized by SDZ 205,557 with a similar pA2 value (7.3). This value was agonist-independent with the exception of (R)-zacopride, against which a significantly lower value (6.4) was observed. 3 In functional studies of 5-HT3 receptors, SDZ 205,557 exhibited an affinity of 6.2 in guinea-pig ileum compared with 6.9 at binding sites labelled by [3H]-quipazine in NG108-15 cells. In the anaesthetized, vagotomized micropig, SDZ 205,557 produced only a transient blockade of 5-HT4-mediated tachycardia. This contrasted with tropisetron, which was active for over 60 min after administration. The half-lives for the inhibitory responses of SDZ 205,557 and tropisetron were 23 and 116 min, respectively. 4 In conclusion, SDZ 205,557 has similar affinity for 5-HT3 and 5-HT4 receptors. The apparent selectivity observed in guinea-pig is due to the atypical nature of the 5-HT3 receptor in this species. The short duration of action of this novel antagonist may complicate its use in vivo. SDZ 205,557 should, therefore, be used with appropriate caution in studies defining the 5-HT4 receptor. Keywords: SDZ 205,557; 5-HT3 receptors; 5-HT4 receptors Introduction The 5-hydroxytryptamine (5-HT) receptor family may be notably, exhibits lower affinities for ligands than either rat or classified into 5-HTI, 5-HT2, 5-HT3 (Bradley et al., 1986) and mouse 5-HT3 receptors (see Kilpatrick & Tyers, 1992, for 5-HT4 subgroups (Bockaert et al., 1992). The 5-HT4 receptor review). This may lead to an overestimation of the selectivity (Dumuis et al., 1988) is stimulated by indoles (such as 5-HT, of antagonists, including SDZ 205,557, in favour of the 5-methoxytryptamine, 5-carboxamidotryptamine), substituted 5-HT4 receptor (Bockaert et al., 1992). In the present study, benzamides (such as renzapride, zacopride, cisapride) and SDZ 205,557 has been further evaluated by use of in vitro azabicycloalkyl benzimidazolones (such as BIMU-1, BIMU- and in vivo responses in various species, on preparations 8), but is insensitive to antagonists of 5-HT1, 5-HT2, and sensitive to 5-HT4 stimulation. This receptor, in contrast to 5-HT3 receptors, such as methysergide, ketanserin and the 5-HT3 receptor, appears to exhibit affinities that are not ondansetron, respectively (see Craig & Clarke, 1990; species-dependent (Bockaert et al., 1992). Bockaert et al., 1992 for reviews). The 5-HT4 receptor is A preliminary account of these studies has been previously competitively antagonized by tropisetron (ICS 205,930; - log published (Eglen et al., 1992). KB= 6.5) and DAU 6285 (-log KB = 6.8; Dumuis et al., 1992). Receptors exhibiting this pharmacological profile have been demonstrated in embryonic mouse colliculi neuronal Methods cultures (Dumuis et al., 1992), guinea-pig ileum (Craig & Clarke, 1990; Eglen et al., 1990) and colon (Elswood et al., Guinea-pig hippocampal adenylyl cyclase 1991), rat oesophagus (Baxter et al., 1991; Waikar et al., 1992), porcine myocardium (Kaumann, 1990), human myo- Male guinea-pigs (Hartley, 250-500 g) were killed by CO2 cardium (Kaumann et al., 1990) and amphibian adrenal asphyxiation. The hippocampi were then rapidly dissected, gland (Idres et al., 1991). More precise definition of 5-HT4 and homogenized (20 strokes) in a glass homogenizer in 9 ml receptors is, however, hampered by the lack of selective, of ice-cold buffer, of the following composition (mM): sucrose competitive antagonists (see Turconi et al., 1991; Bockaert et 300, Tris-HCl 20, EGTA 1, Na2EDTA 2.5 and dithiothreitol al., 1992 for reviews). 1 (pH 7.4, 23°C). This homogenate was then diluted, 1:8 Buchheit et al. (1991) reported that SDZ 205,557 (2- (v/v) with buffer and centrifuged (10 min, 39,000 g, 4C). The methoxy4-amino-5-chloro benzoic acid 2-(diethylamino) ethyl pellet was resuspended in 9 ml of buffer and the membrane ester) selectively antagonized 5-HT4 receptors in guinea-pig suspension used directly in the adenylyl cyclase assay. isolated ileum with an affinity (- log KB) of 7.5. This affinity Antagonists were added 30 min prior to addition of agonist. was greater than that at 5-HT3 receptors in this tissue (- log Measurements of adenylyl cyclase activity were performed, KB = 6.0). SDZ 205,557 lacked affinity at 5-HTI or 5-HT2 three times, according to the method of Alvarez & Daniels receptors and was, therefore, suggested as a useful ligand to (1990) with each sample run in triplicate. The final composi- define the 5-HT4 receptor (Buchheit et al., 1992). Phar- tion of the incubation medium was (mM): [at32P]-adenosine macological evidence suggests that 5-HT3 receptors are a 5'-triphosphate ([&32P]-ATP, 0.25 pCi) 0.5, MgSO4 5, Tris- family of species variants. The guinea-pig 5-HT3 receptor, HCl 44 (pH 7.4), 1-methyl-3-isobutylxanthine 1.0, sucrose 50, EDTA 1.0, EGTA 0.2, dithiothreitol 0.2, adenosine 3':5'- cyclic monophosphate (cyclic AMP) 2, guanosine 5'-triphos- I Author for correspondence. phate (GTP) 0.1, phosphoenol pyruvate 20 and pyruvate ACTION OF SDZ 205,557 AT 5-HT3 AND 5-HT4 RECEPTORS 377 kinase 6 units ml-'. The reaction was initiated by the sequen- 205,557 were used, and the slope of the Schild plot deter- tial addition of the membrane suspension (40 #Al) to the mined by regression analysis. incubation medium in a total reaction volume of 200 Jl. Incubations were performed for 30 min at 370C and ter- Competition radioligand binding studies minated by the addition of 20 ftl of a stock solution of [3H]-cyclic AMP (0.005 JCi) in 2.2 N HCl. Labelled cyclic Membranes were prepared from NG108-15 cells cultured AMP was added to estimate and correct for recovery of the under conditions described previously (Sharif et al., 1991). In nucleotide following column chromatography. The tube con- competition binding studies, 5-HT3 receptors in NG108-15 tents were heated at 95C for 4 min and then cooled in an cell membranes were labelled with 0.5 nM [3H]-quipazine and ice-water bath. Neutral alumina (1.3 g) was dispensed into non-specific binding was defined by 1 JAM (S)-zacopride. The disposable polypropylene columns with a Uniflow adjustable membrane homogenates were incubated in 25 mM Tris-Krebs powder measure. The columns were placed on a plexiglas (pH 7.4 at 250C) with radioligand and varying concentrations rack designed to hold the columns and to fit over a box of of SDZ 205,557, or other standard 5-HT3 receptor anta- 100 scintillation vials. An aliquot (200 pl) of the solution gonists, in a final assay volume of 0.5 ml. The incubations contained in each tube was pipetted onto the columns and were carried out for 45 min at 250C and were terminated by allowed to flow into the dry alumina. Cyclic AMP was then rapid vacuum filtration over Whatman GF/B filters using a eluted with 4 ml of 0.1 M ammonium acetate, pH 7. The Brandell 48 cell harvester. This was immediately followed by effluent (3.2 ml) was collected into scintillation vials, mixed 8 s of washing with ice-cold 0.1 M NaCl. The filters were with 15 ml scintillation fluid and counted for 3H and 32p in a pretreated with 0.3% polyethyleneimine in order to reduce liquid scintillation spectrometer. filter binding of the radioligand and the radioactivity retained on the filters was determined by liquid scintillation spect- rometry. All competition data were analyzed by iterative Rat isolated oesophageal muscularis mucosae curve fitting procedure as described previously (Michel & Whiting, 1984). The apparent dissociation constant (K.) of The method used was that previously described by Baxter et competing ligands was calculated from ICso values by the al. (1991). Male rats (Sprague-Dawley, 200-250 g) from Cheng-Prusoff equation (Cheng & Prusoff, 1973). Charles River were killed by CO2 asphyxiation, the thoracic oesophagus removed and placed in Tyrode solution (com- Anaesthetized micropig studies position, mM: NaCl 139.0, KCl 2.7, MgCl2 6H2O 1.1, NaH2PO4 0.4, glucose 5.6, NaHCO3 11.8 and CaCl2-6H2O The method used was modified from that described by Villa- 1.8). The outer proprial muscle coat was cut longitudinally lon et al. (1990). Yucatan micropigs (male and female; and gently peeled away, leaving the inner muscularis 14.9-20.8 kg, Charles River Laboratories Inc., Wilmington, mucosae. Silk threads were then tied through the lumen on MA, U.S.A.) were pretreated with ketamine HCl (approx. both ends of the tissues, which were then mounted vertically 30 mg kg-', i.m.), anaesthetized with pentobarbitone sodium in 10 ml tissue baths containing Tyrode solution with 1 JAM (20 mg kg-') via a marginal ear vein, intubated, and methysergide, 30 gM cocaine and 30 JM corticosterone.
Recommended publications
  • Granisetron "Vianex"
    EU‐RISK MANAGEMENT PLAN GRANISETRON VIANEX® 1 MG/ML, SOLUTION FOR INJECTION/ INFUSION precautionary measure, breast‐feeding should not be advised during treatment with Granisetron “Vianex”. Legal Status: Prescription only product. VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Nausea and vomiting associated with chemotherapy and radiotheraphy: One of the most distressing symptoms for patients undergoing both surgery and chemotherapy is nausea and vomiting. These symptoms have a significant impact on quality of life and can lead to malnutrition, inability to respond to treatment and an increased length of hospitalization. Emesis is more commonly associated with chemotherapeutic agents; however, radiation‐induced nausea and vomiting (RINV) can affect a significant proportion of patients, depending on the treated area, dose fractionation, and volume of radiotherapy. The relative risk for developing nausea and vomiting with chemotherapy ranges from 30 to 90% and is dependent upon the chemotherapeutic agent used. Relative risk for nausea and vomiting with radiation therapy is approximately 40%.2,3,4,5 Post‐operative nausea and vomiting Postoperative nausea and vomiting (PONV) is a major source of patient dissatisfaction and is the leading cause of discharge delays and unanticipated postsurgical hospital admissions. In the absence of pharmacological treatment, the rate of PONV is approximately 30% in general population, and can be as high as 70% in patients at highest risk. Several risk factors as surgery type, female gender, non‐smoker status, history of postoperative nausea and vomiting or motion sickness and post‐operative opioid use have been acknowledged. Additionally, post‐ operative vomiting (POV) occurs twice as frequently in children as in adults, increasing until puberty and then decreasing to adult incidence rates.
    [Show full text]
  • Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: a PET Study in Conscious Monkeys
    Neuropsychopharmacology (2013) 38, 2666–2674 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Subanesthetic Doses of Ketamine Transiently Decrease Serotonin Transporter Activity: A PET Study in Conscious Monkeys 1 1 1 1 1 Shigeyuki Yamamoto , Hiroyuki Ohba , Shingo Nishiyama , Norihiro Harada , Takeharu Kakiuchi , 1 ,2 Hideo Tsukada and Edward F Domino* 1 2 Central Research Laboratory, Hamamatsu Photonics KK, Hamakita, Japan; Department of Pharmacology, University of Michigan, Ann Arbor, MI, USA Subanesthetic doses of ketamine, an N-methyl-D-aspartic acid (NMDA) antagonist, have a rapid antidepressant effect which lasts for up to 2 weeks. However, the neurobiological mechanism regarding this effect remains unclear. In the present study, the effects of subanesthetic doses of ketamine on serotonergic systems in conscious monkey brain were investigated. Five young monkeys 11 underwent four positron emission tomography measurements with [ C]-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)benzoni- 11 trile ([ C]DASB) for the serotonin transporter (SERT), during and after intravenous infusion of vehicle or ketamine hydrochloride in a 11 dose of 0.5 or 1.5 mg/kg for 40 min, and 24 h post infusion. Global reduction of [ C]DASB binding to SERT was observed during ketamine infusion in a dose-dependent manner, but not 24 h later. The effect of ketamine on the serotonin 1A receptor (5-HT1A-R) and dopamine transporter (DAT) was also investigated in the same subjects studied with [11C]DASB. No significant changes were observed in either 5-HT -R or DAT binding after ketamine infusion. Microdialysis analysis indicated that ketamine infusion transiently increased 1A serotonin levels in the extracellular fluid of the prefrontal cortex.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE in PETS Introduction Pathophysiology/Etiology to That Observed in Dogs
    VETTALK Volume 15, Number 04 American College of Veterinary Pharmacists THE HARD TRUTH ABOUT PROKINETIC MEDICATION USE IN PETS Introduction Pathophysiology/Etiology to that observed in dogs. It can be The moving topic of this Vet Talk As with most diseases in the veteri- due to a trichobezoar, dehydration, newsletter will be prokinetic medica- nary world, the etiology and patho- obesity, old age, diabetes, immobility, tions. The availability of information physiology of constipation are varied pain from trauma to the low back, on the many prokinetic agents is var- depending on the species being dis- bladder infection, or an anal sac infec- ied at best so an overall consensus of cussed, where in their gastrointestinal tion. In cases that are more chronic, prokinetic medications will be as- tract the problem is occurring, and underlying disease such as colitis or sessed in this article, hopefully giving any accompanying comorbid condi- Irritable Bowel Syndrome (IBS) may better insight to practitioners about tions. be the culprit. On the other hand, the which agents to use in their patients. cause may be idiopathic which is Canines: In man’s best friend, consti- frustrating for both veterinarian and Prevalence pation has many origins. A dog’s patient since this form is most diffi- Chronic constipation and gastroin- digestive tract itself is complex but cult to treat. testinal stasis are highly debilitating ultimately the mass movements and conditions that not only affect human haustral contractions from the large Equines: Despite their large size, patients but our four legged patients intestine (colon), propel feces into the horses have incredibly delicate diges- as well! Though this condition is rectum stimulating the internal anal tive systems.
    [Show full text]
  • Potential Cannabis Antagonists for Marijuana Intoxication
    Central Journal of Pharmacology & Clinical Toxicology Bringing Excellence in Open Access Review Article *Corresponding author Matthew Kagan, M.D., Cedars-Sinai Medical Center, 8730 Alden Drive, Los Angeles, CA 90048, USA, Tel: 310- Potential Cannabis Antagonists 423-3465; Fax: 310.423.8397; Email: Matthew.Kagan@ cshs.org Submitted: 11 October 2018 for Marijuana Intoxication Accepted: 23 October 2018 William W. Ishak, Jonathan Dang, Steven Clevenger, Shaina Published: 25 October 2018 Ganjian, Samantha Cohen, and Matthew Kagan* ISSN: 2333-7079 Cedars-Sinai Medical Center, USA Copyright © 2018 Kagan et al. Abstract OPEN ACCESS Keywords Cannabis use is on the rise leading to the need to address the medical, psychosocial, • Cannabis and economic effects of cannabis intoxication. While effective agents have not yet been • Cannabinoids implemented for the treatment of acute marijuana intoxication, a number of compounds • Antagonist continue to hold promise for treatment of cannabinoid intoxication. Potential therapeutic • Marijuana agents are reviewed with advantages and side effects. Three agents appear to merit • Intoxication further inquiry; most notably Cannabidiol with some evidence of antipsychotic activity • THC and in addition Virodhamine and Tetrahydrocannabivarin with a similar mixed receptor profile. Given the results of this research, continued development of agents acting on cannabinoid receptors with and without peripheral selectivity may lead to an effective treatment for acute cannabinoid intoxication. Much work still remains to develop strategies that will interrupt and reverse the effects of acute marijuana intoxication. ABBREVIATIONS Therapeutic uses of cannabis include chronic pain, loss of appetite, spasticity, and chemotherapy-associated nausea and CBD: Cannabidiol; CBG: Cannabigerol; THCV: vomiting [8]. Recreational cannabis use is on the rise with more Tetrahydrocannabivarin; THC: Tetrahydrocannabinol states approving its use and it is viewed as no different from INTRODUCTION recreational use of alcohol or tobacco [9].
    [Show full text]
  • Exploring the Cocrystallization Potential of Urea and Benzamide
    JMolModel (2016) 22:103 DOI 10.1007/s00894-016-2964-6 ORIGINAL PAPER Exploring the cocrystallization potential of urea and benzamide Piotr Cysewski1 & Maciej Przybyłek1 & Dorota Ziółkowska 2 & Karina Mroczyńska2 Received: 14 November 2015 /Accepted: 14 March 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract The cocrystallization landscape of benzamide and defined by excess thermodynamic functions, and all known urea interacting with aliphatic and aromatic carboxylic acids cocrystals are outside of this range belonging to the third or was studied both experimentally and theoretically. Ten new fourth quartile. On the contrary, such a simple separation of cocrystals of benzamide were synthesized using an oriented positive and negative cases of benzamide miscibility in the samples approach via a fast dropped evaporation technique. solid state is not observed. The difference in properties be- Information about types of known bi-component cocrystals tween urea and benzamide R2,2(8) heterosynthons is also augmented with knowledge of simple binary eutectic mixtures documented by alterations of substituent effects. was used for the analysis of virtual screening efficiency Intermolecular interactions of urea with para substituted among 514 potential pairs involving aromatic carboxylic acids benzoic acid analogues are stronger compared to those of interacting with urea or benzamide. Quantification of intermo- benzamide. Also, the amount of charge transfer from amide lecular interaction was achieved by estimating the excess ther- to aromatic carboxylic acid and vice versa is more pronounced modynamic functions of binary liquid mixtures under for urea. However, in both cases, the greater the electron with- supercooled conditions within a COSMO-RS framework.
    [Show full text]
  • The Alcohol Withdrawal Syndrome
    Downloaded from jnnp.bmj.com on 4 September 2008 The alcohol withdrawal syndrome A McKeon, M A Frye and Norman Delanty J. Neurol. Neurosurg. Psychiatry 2008;79;854-862; originally published online 6 Nov 2007; doi:10.1136/jnnp.2007.128322 Updated information and services can be found at: http://jnnp.bmj.com/cgi/content/full/79/8/854 These include: References This article cites 115 articles, 38 of which can be accessed free at: http://jnnp.bmj.com/cgi/content/full/79/8/854#BIBL Rapid responses You can respond to this article at: http://jnnp.bmj.com/cgi/eletter-submit/79/8/854 Email alerting Receive free email alerts when new articles cite this article - sign up in the box at service the top right corner of the article Notes To order reprints of this article go to: http://journals.bmj.com/cgi/reprintform To subscribe to Journal of Neurology, Neurosurgery, and Psychiatry go to: http://journals.bmj.com/subscriptions/ Downloaded from jnnp.bmj.com on 4 September 2008 Review The alcohol withdrawal syndrome A McKeon,1 M A Frye,2 Norman Delanty1 1 Department of Neurology and ABSTRACT every 26 hospital bed days being attributable to Clinical Neurosciences, The alcohol withdrawal syndrome (AWS) is a common some degree of alcohol misuse.5 Despite this Beaumont Hospital, Dublin, and management problem in hospital practice for neurologists, Royal College of Surgeons in substantial problem, a survey of NHS general Ireland, Dublin, Ireland; psychiatrists and general physicians alike. Although some hospitals conducted in 2000 and 2003 indicated 2 Department of Psychiatry, patients have mild symptoms and may even be managed that only 12.8% had a dedicated alcohol worker.6 In Mayo Clinic, Rochester, MN, in the outpatient setting, others have more severe addition, few guidelines exist promoting the USA symptoms or a history of adverse outcomes that requires initiation of clear and uniform AWS treatment 7–9 Correspondence to: close inpatient supervision and benzodiazepine therapy.
    [Show full text]
  • Imidazol-1-Ylethylindazole Voltage-Gated Sodium Channel
    Article pubs.acs.org/jmc Terms of Use CC-BY Imidazol-1-ylethylindazole Voltage-Gated Sodium Channel Ligands Are Neuroprotective during Optic Neuritis in a Mouse Model of Multiple Sclerosis Lorcan Browne,† Katie Lidster,‡ Sarah Al-Izki,‡ Lisa Clutterbuck,† Cristina Posada,† A. W. Edith Chan,† Dieter Riddall,† John Garthwaite,† David Baker,‡ and David L. Selwood*,† † Biological and Medicinal Chemistry, Wolfson Institute for Biomedical Science, University College London, Gower Street, London WC1E 6BT, United Kingdom ‡ Neuroimmunology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, United Kingdom *S Supporting Information ABSTRACT: A series of imidazol-1-ylethylindazole sodium channel ligands were developed and optimized for sodium channel inhibition and in vitro neuroprotective activity. The molecules exhibited displacement of a radiolabeled sodium channel ligand and selectivity for blockade of the inactivated state of cloned neuronal Nav channels. Metabolically stable analogue 6 was able to protect retinal ganglion cells during optic neuritis in a mouse model of multiple sclerosis. ■ INTRODUCTION Voltage-gated sodium (Nav) channels are the fundamental generators of electrical impulses (action potentials) in the membranes of excitable cells. A number of clinically used drugs ff exert their therapeutic e ects through Nav. These drugs are primarily used in the treatment of central nervous system (CNS) disorders, such as epilepsy and neuropathic pain, but are increasingly being scrutinized as potential treatments for neurodegenerative conditions occurring acutely, such as in ischemic stroke, or chronically, as in multiple sclerosis (MS).1 Phenytoin 1 was one of the first antiepileptics developed (Figure 1).
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • Download Our Value Formulary
    VALUE FORMULARY EFFECTIVE JULY 1, 2021 www.amerihealthnj.com INFORMATION FOR MEMBERS AND PROVIDERS The Value Formulary Guide is intended to help members and providers understand prescription drug coverage under the AmeriHealth New Jersey Value formulary. We are committed to providing comprehensive prescription drug coverage. To achieve this, we include a formulary feature in your prescription drug benefit. The drugs are approved by the U.S. Food and Drug Administration (FDA). They are also reviewed by our Pharmacy and Therapeutics Committee, a group of doctors and pharmacists from the area. These prescription drugs have been added to the Value Formulary for their reported medical effectiveness, safety, and value. FutureScripts®, an independent company, is our pharmacy benefits manager. They monitor all drugs to ensure they are safe and effective drugs. Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage. Drug coverage is based on medical necessity. This formulary guide was current at the time of printing and is subject to change. Please call Customer Service at the number listed on the back of your ID card if you have any questions about your prescription drug benefits. Please discuss any questions or concerns about your drug therapy with your provider or pharmacist. What is a formulary? A formulary is a list of prescribed medications or other pharmacy care products, services or supplies chosen for their safety, cost, and effectiveness. Medications are listed by categories or classes and are placed into cost levels known as tiers. It includes both brand and generic prescription medications.
    [Show full text]
  • Synthesis of Some Aiæides of Gentisio Aoid Dissertation
    SYNTHESIS OF SOME AIÆIDES OF GENTISIO AOID DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By ALLEN I. DHŒS, B. S., M. Sc, ****** The Ohio State Uhiversity 1958 Approved by: Department of Pharmaoy ACKNOV/LEDaMTS I wish to acknowledge the generous advice and assistance rendered by Dr. Frank V/. Bope, Associate Professor of Pharmacy, in the development of this dissertation. To the American Foundation for Pharmaceutical Education, I wish to express my gratitude for extending to me financial assistance in the form of a Fellowship— without this assistance it would not have been possible for me to complete my graduate studies. To the members of the faculty of the College of Pharmacy of The Ohio State University, I wish to express my sincere appreciation for their guidance throughout my graduate studies, I also wish to eatress my sincere thanks and grate­ ful appreciation to all others who have assisted me in any way. As a final note, I would like to thank my wife, Charlotte, for her wonderful moral support during the com­ pletion of my graduate studies; for behind every man there is his wife. ii TABLE OF CONTENTS Page INTRODUCTION .......... 1 DISCUSSION OF LITERATURE General ........................ 3 Some New Gentisio Aoid Derivatives 15 Preparation of Amides .......... 16 GENERAL PROCEDURES 21 EXPERIMENTAL 23 Preparation of 2,5- Dimethoiybenzoio Acid . , 23 Preparation of 2,5- Dimethoxybenzoyl Chloride 26 Classification of N- Substituted Amides Prepared 27 Monosubstituted Amides of 2,5- Dimethoxybenzoio A o i d ........................................ 29 Alkyl .....................................
    [Show full text]
  • Basic Analytical Toxicology
    The World Health Organization is a specialized agency of the United Nations with primary responsibility for international health matters and public health. Through this organization, which was created in 1948, the health professions of some 190 countries exchange their knowledge and experience with the aim of making possible the attainment by all citizens of the world by the year 2000 of a level of health that will permit them to lead a socially and economically productive life. By means of direct technical cooperation with its Member States, and by stimulating such coopera­ tion among them, WHO promotes the development of comprehensive health services, the prevention and control of diseases, the improvement of environmental conditions, the development of human resources for health, the coordination and development of biomedical and health services research, and the planning and implementation of health programmes. These broad fields of endeavour encompass a wide variety of activities, such as developing systems of primary health care that reach the whole population of Member countries; promoting the health of mothers and children; combating malnutrition, controlling malaria and other communicable diseases including tuberculosis and leprosy; coordinating the global strategy for the prevention and control of AIDS; having achieved the eradication of smallpox, promoting mass immunization against a number of other preventable diseases; improving mental health; providing safe water supplies; and training health personnel of all categories. Progress towards better health throughout the world also demands international cooperation in such matters as establishing international standards for biological substances, pesticides and pharma­ ceuticals; formulating environmental health criteria; recommending international nonproprietary names for drugs; administering the International Health Regulations; revising the International Statistical Classification of Diseases and Related Health Problems and collecting and disseminating healih statistical information.
    [Show full text]